NCT03460483View on ClinicalTrials.gov

Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care

NACompletedINTERVENTIONAL
Enrollment

1,001

Participants

Timeline

Start Date

March 30, 2018

Primary Completion Date

June 15, 2025

Study Completion Date

June 15, 2025

Conditions
Endometrial AdenocarcinomaEndometrial CarcinomaLynch SyndromeRelatives
Interventions
OTHER

Genetic Counseling

Undergo genetic counseling

OTHER

Genetic Testing

Undergo genetic testing

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Mutation Carrier Screening

Undergo tumor screening via next-generation sequencing

Trial Locations (9)

43210

Ohio State University Comprehensive Cancer Center, Columbus

43214

Ohio Health, Columbus

43608

Mercy Health - St. Vincent Medical Center, Toledo

44106

University Hospitals Cleveland Medical Center, Cleveland

44109

MetroHealth Medical Center, Cleveland

44304

Summa Akron City Hospital/Cooper Cancer Center, Akron

44710

Aultman Health Foundation, Canton

45219

University of Cincinnati, Cincinnati

45245

TriHealth Cancer Institute-Westside, Cincinnati

All Listed Sponsors
lead

Ohio State University Comprehensive Cancer Center

OTHER

NCT03460483 - Universal Endometrial Cancer DNA Sequencing for Detection of Lynch Syndrome and Personalized Care | Biotech Hunter | Biotech Hunter